GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001

GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001

26,400.000ARSD
+975.000+3.83%
At close at Jan 10, 20:00 UTC
ARS
No trades
See on Supercharts
Market capitalization
‪116.20 T‬ARS
−48.931ARS
‪1.67 T‬ARS
‪7.97 T‬ARS
Beta (1Y)
0.25

About Gilead Sciences, Inc.


CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Founded
1987
ISIN
ARBCOM4601C4
FIGI
BBG00P4J9730
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Performance
‪−105%‬
‪−70%‬
‪−35%‬
‪0%‬
‪35%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−4.00 T‬‬
‪0.00‬
‪‪4.00 T‬‬
‪‪8.00 T‬‬
‪‪12.00 T‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.00 T‬‬
‪‪4.00 T‬‬
‪‪6.00 T‬‬
‪‪8.00 T‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.00 T‬‬
‪‪4.00 T‬‬
‪‪6.00 T‬‬
‪‪8.00 T‬‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪6.00 T‬‬
‪‪12.00 T‬‬
‪‪18.00 T‬‬
‪‪24.00 T‬‬
Debt
Free cash flow
Cash & equivalents

No news here

Looks like there's nothing to report right now

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GILD4184056
Gilead Sciences, Inc. 3.5% 01-FEB-2025
Yield to maturity
8.49%
Maturity date
Feb 1, 2025
GILD5050849
Gilead Sciences, Inc. 2.8% 01-OCT-2050
Yield to maturity
7.19%
Maturity date
Oct 1, 2050
US375558BS1
GILEAD SCIEN 20/40
Yield to maturity
6.86%
Maturity date
Oct 1, 2040
US375558BK8
GILEAD SCIENCES 16/47
Yield to maturity
6.49%
Maturity date
Mar 1, 2047
GILD4184058
Gilead Sciences, Inc. 4.5% 01-FEB-2045
Yield to maturity
6.28%
Maturity date
Feb 1, 2045
GISE
GILEAD SCIENCES 2046
Yield to maturity
6.24%
Maturity date
Mar 1, 2046
GILD4104362
Gilead Sciences, Inc. 4.8% 01-APR-2044
Yield to maturity
6.19%
Maturity date
Apr 1, 2044
GILD5939386
Gilead Sciences, Inc. 5.6% 15-NOV-2064
Yield to maturity
6.08%
Maturity date
Nov 15, 2064
GISG
GILEAD SCIENCES 16/36
Yield to maturity
5.97%
Maturity date
Sep 1, 2036
GILD5939385
Gilead Sciences, Inc. 5.5% 15-NOV-2054
Yield to maturity
5.95%
Maturity date
Nov 15, 2054
GILD5648609
Gilead Sciences, Inc. 5.55% 15-OCT-2053
Yield to maturity
5.91%
Maturity date
Oct 15, 2053

Explore more bonds